OKYO Pharma LTD: OKYO Pharma Limited (OKYO or the Company) - Grant of options

LONDON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye

Related Keywords

United Kingdom ,London ,City Of ,Robert Emmet ,John Brancaccio ,Gabriele Cerrone ,Raj Patil ,Keeren Shah ,Garys Jacob ,Bernard Denoyer ,London Stock Exchange ,Pharma Limited ,Redchip Companies Inc ,Optiva Securities ,Remuneration Committee ,Company The Board Or Directors ,Chief Scientific ,Chief Financial ,Chief Executive ,Investor Relations ,Official List ,United Kingdom Financial Conduct Authority ,Dry Eye Disease ,Tokyo ,Dharma ,Imited ,Company ,Rant ,Options ,Director ,Dmr ,Dealings ,